Evolution and ecology in treating cancer

Robert Gatenby, MD
Moffitt Cancer Center

IMAGING RESEARCH
MOFFITT CANCER CENTER

The problem: Disseminated cancer is a fatal disease: Evolution almost always defeats therapy



Note:

1. Large number of tumor sites
2. Spatial diversity of response and progression
3. Key role of imaging

Topics

1. Cancer as a complex dynamical system
2. Understanding complex systems requires:
    - Data
    - First Principles
    - Computational methods
3. Clinical applications.

Dear Sir Philada. Feb. 13. 1750

You desire to know my Thoughts about the N.E. Storms beginning to Leeward. Some Years since there was an Eclipse of the Moon at 9 in the Evening, which I intended to observe, but before 8 a Storm blew up at N E. and continued violent all Night and all next Day, the Sky thick clouded, dark and rainy, so that neither Moon nor Stars could be seen. The Storm did a great deal of Damage all along the Coast, for we had Accounts of it in the News Papers from Boston, Newport, New York, Maryland and Virginia. But what surpriz'd me, was to find in the Boston Newspapers an Account of an Observation of that Eclipse made there: For I thought, as the Storm came from the N E. it must have begun sooner at Boston than with us, and consequently have prevented such Observation. I wrote to my Brother about it, and he inform'd me, that the Eclipse was over there, an hour before the Storm began.

Franklin was among the first to recognize the error of applying simple linear thinking to complex, non-linear dynamical systems,

But not the last

Learning from meteorology

- Weather is a dynamic, complex and non linear system - but predicting weather is mundane
- Forecasting has greatly improved through large data sets, physical first principles (N-S equations), and constant updating of predictions with new data

Cancer as a complex, adaptive system – the math/oncology interface

- Human intuition is poorly adapted to predict dynamics in non-linear systems.
- Leads to overly simplistic views – e.g. the genetic model of cancer.
- We need computational models
- Mathematicians typically are distant from biologists
- Leads to modeling that simply accepts the simplistic biological paradigms
- Mathematicians proposing novel dynamics often have little connection to the biology.

Integrated Mathematical Oncology (IMO) at Moffitt – Embedding mathematicians in a cancer center

- Cancer is complicated and complex but not incomprehensible!
- First principles will exist
- Quantitative models linked to experimental and clinical data are necessary to define tumor dynamics
- Evolution provides a unifying framework – first principles
- Imaging, by non-destructively defining spatial and temporal heterogeneity, is the key experimental tool





A “hurricane model” for every patient

Principle Components:

- Big data – spatial and temporal
- Dynamics from first principles
- Timely and clinically accessible computation models predicting optimal therapy
- Constant feedback comparing prediction to outcomes









Conventional molecular/genetic approach to “personalized” cancer therapy



Is this the data we need?

Questions

- What was the heterogeneity of EGFR mutation within and between the metastases?
- What other factors affected response?
- Could progression free survival be increased with treatments other than constant maximum dose erlotinib? Was SOC dosing the best strategy available?
- Now what???



Data: Recent recognition of intratumoral molecular heterogeneity



"Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor"

Gerlinger, et al. NEJM, 2012

"…extensive intratumor heterogeneity, with most patients displaying different GB subtypes within the same tumor."



Sottoriva et al. PNAS, 2013

Bad news:

1. Each examined tumor is spatially heterogeneous
2. Each examined tumor is dead

Data and dynamics. What is the source of heterogeneity?: Intratumoral evolution generally ascribed mutations (“mutator phenotype”)





More bad news: If intratumoral evolution is driven by random mutations, spatial heterogeneity in molecular properties is fundamentally stochastic and unpredictable

Darwinian Dynamics can be studied without genetics



- **Heritable Variation in phenotypes (note reaction norms in cancer and normal cells)**
- **Fitness is contextual - depending on environmental selection forces**

Defining data: What does genetics tell us and not tell us?

Note : Dandelions are asexual and triploid

Optimal data is non-destructive, readily available and spatially or temporally explicit

.





Goal: Maximize value of data. Intratumoral heterogeneity as a function of environmental variation (blood flow)





Blood flow and cytotype may be linked using evolutionary principles

Imaging to define intratumoral ecology (habitats)

- T1-Post gad is a metric of blood flow and substrate availability
- T2, Diffusion weighted, and FLAIR sequences are measures of cellularity and interstitial edema
- Superimposing the images could generate ecological maps of environmental selection forces and size of adapted populations





Using clinical imaging to define spatial variations in tumors



COURTESY OF MU ZHAO

Each habitat can be projected back into the tumor image



3D SPACE



Habitat Imaging in GBM
(fuzzy c-means clustering)



Habitat distribution predicts survival









Temporal dynamics: GBM habitats change dramatically after radiation/chemotherapy



Applying first principles: Despite the critical role of evolution in therapy failure, evolutionary dynamics virtually never enter clinical design

Overlooking evolution: A systematic analysis of cancer relapse and therapeutic resistance research

C. Athena Aktipis[1,2], Virginia S. Y. Kwan[1], Kathryn A. Johnson[1], Steven L. Neuberg[1], Carlo C. Maley[2]

- Cancer therapy selects for cancer cells resistant to treatment, a process that is fundamentally evolutionary. To what extent, however, is the evolutionary perspective employed in research on therapeutic resistance and relapse? We analyzed 6,228 papers about therapeutic resistance and/or relapse in cancers and found that the use of evolution terms in abstracts has remained at about 1% since the 1980s. However, detailed coding of 22 recent papers revealed a higher proportion of papers using evolutionary methods or evolutionary theory, although this number is still less than 10%. Despite the fact that relapse and therapeutic resistance is essentially an evolutionary process, it appears that this framework has not permeated research. This represents an unrealized opportunity for advances in research on therapeutic resistance.

Applying evolutionary principles to cancer therapy:

Consider the diamondback moth (*Plutella xylostella*)

- Probably of European origin -first observed in North America in 1854 in Illinois . Eats cabbage
- The moth has been treated with a wide range of chemicals with transient success
- It has now spread throughout North America causing serious damage to cabbage crops
- In 1988 the moth was reported to be resistant to all known insecticides
- A moth infestation is incurable. Current treatments limit pesticide application to reduce crop damage

Invasive pests are now managed using principles of Integrated Pest Management (IPM): lessons from the alfalfa weevil

- “The presence of alfalfa weevils in an alfalfa field does not in itself justify pesticide application.”
- “Chemical control should not be used unless weevil damage approaches the level that will reduce net profit by at least the cost of a pesticide application”
- “Several species of wasps and a parasite of the adult weevil (*Microctonus aethiopoides*), have been introduced. In most cases, these natural enemies will help keep infestations below economically damaging levels”

Lessons from Integrated Pest Management – Strategic Therapy

1. Eradication of a disseminated invasive pest is virtually never successful
2. Heterogeneity in pest phenotype and environmental conditions will result in resistance to virtually any therapy.
3. Control is possible but requires treatment strategies explicitly designed for that purpose
4. Kill not the maximum number of pests but the minimum necessary
5. “Biological controls” are more effective than chemical

Traditional Cancer therapy: high dose density

Maximum tolerable dose in shortest period of time

Minimize probability of mutation conferring resistance.

Three critical assumptions:

1. Resistant populations are not present prior to therapy
2. Resistance is acquired as a step-wise mutation
3. The resistant phenotype rapidly proliferates and results in patient death.

Why does high dose therapy fail? Competitive release



- Resistant cells are present prior to therapy due to phenotypic diversity or microenvironmental factors or both.
- High dose therapy eliminates sensitive population
- Resistant populations, although less fit, are left unopposed to proliferate and repopulate the tumor

IPM for tumor treatment: “Evolution of resistance is inevitable but proliferation is not”: Key parameter is cost of resistance

- Any resistance mechanisms requires resources
- Resources diverted to resistance are not available for proliferation
- In the absence of therapy, the resistant populations will generally be less fit
- The cost of resistance manifests in various ways depending on the therapy





Adaptive therapy: Kill the minimum necessary and exploit their fitness advantage over resistant phenotypes



Sensitive Cell

Resistant Cell

- Low dose chemotherapy
  - Less toxicity? Limit sensitive cell death
- Attempt to maintain stable tumor burden
- Chemotherapy sensitive cells suppress resistant cell growth
- Induce near steady state of patient-tumor interaction

In vivo application





Mathematical Models

High dose density results in shortest patient survival – killing sensitive cells leaves adaptive landscape open to rapid proliferation by resistant phenotype

Adaptive therapy –abandon curative intent - limit therapy to stabilizing sensitive population which then suppresses growth of resistant clones

Experiments:

Adaptive therapy achieves long term survival with decreasing dose of carboplatin

Latest application to breast cancer. Exploit cost of MDR using ersatzdroges!







Double bind strategy: the immune system as predator

Introduce a cat



The squirrel adapts

Solution **Introduce a snake**

Moffitt Study

- Protocol: 29 patients with small cell lung cancer after failed first line therapy. Treated with 3 months of p53 vaccine
- Results: Serum evidence of immune response in all patients but only one partial response by change in tumor size



Fortuitously, the patients were followed after exiting the trial. 21 received 2nd or 3rd line chemotherapy. Historical experience predicts a response rate of <5%

Table 3. Response to second-line chemotherapy in vaccinated patients

All patients who received chemotherapy after vaccine (n = 21)		Platinum-resistant patients who received chemotherapy after vaccine (n = 13)	
Response	n (%)	Response	n (%)
CR	3 (14.3)	CR	1 (8)
PR	10 (47.6)	PR	7 (54)
SD	4 (19.05)	SD	3 (23)
PD	4 (19.05)	PD	2 (15)
CR + PR	13 (61.9)	CR + PR	8 (61.5)

Abbreviations: PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response (all according to Response Evaluation Criteria in Solid Tumors).

Is this a double bind?

- Mutant p53 is known to confer drug resistance. Adaptation to vaccine resulted in lower p53 expression and increased drug sensitivity
- Chemotherapy reduces immuno-suppressive intra-tumoral T lymphocytes enhancing the immune response
- Proposals: 1. Same study, repeat vaccine after chemo. 2. Give chemo prior to vaccine

Predator facilitation can generate an “evolutionarily futile cycle”



- Initial therapy kills tumor cell and selects for resistant populations with a known strategy
- Follow with a therapy focused on the adaptation
- Repeat as necessary

Clinical application: For every cancer patient, a “hurricane” model

- Maximal use of available data with focus on temporal and spatial heterogeneity
- Integrate data based on evolutionary and ecological principles as well as historical data (cohort studies)
- Always predict forward
- Constantly check predictions with new data





So, how does this work?



Ariosto Silva, IMO

Within this data set, alternative therapeutic strategies are suggested in some patients but cannot evaluate CR and NR individuals









Computational model suggests optimal therapeutic dosing schedule would have improved outcomes in 3 separate trials







Constructing prospective patient-specific computational models using bone marrow biopsies and aspirates

Key parameter estimates:

1. Drug delivery

   Microvessel density

2. EMDR

   Fibronectin concentration and spatial distribution

3. Phenotypic resistance

   HR karyotype (FISH)
   PgP expression

4. Phenotypic resistance

   Microfluidic tesing of aspirated cells



Patient-specific therapy



Computational models







Thank you

Moffitt
Ariosto Silva
Yoonseok Kam
Mark Lloyd
Jessica Cunningham
Bob Gillies

UCSF
Athena Atkipis
Carlo Maley

UIC
Joel Brown
Paul Orlando

USF
Larry Hall
Dmitry Goldgoff
Mu Zhou

Funding
NCI (PSOC,PQ,QIN)
McDonnell Foundation